About arbutus biopharma - ABUS
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
ABUS At a Glance
Arbutus Biopharma Corp.
701 Veterans Circle
Warminster, Pennsylvania 18974
| Phone | 1-267-469-0914 | Revenue | 6.17M | |
| Industry | Pharmaceuticals: Major | Net Income | -69,920,000.00 | |
| Sector | Health Technology | Employees | 44 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ABUS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 98.354 |
| Price to Book Ratio | 6.38 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.15 |
| Enterprise Value to Sales | 79.474 |
| Total Debt to Enterprise Value | 0.012 |
ABUS Efficiency
| Revenue/Employee | 140,250.00 |
| Income Per Employee | -1,589,090.909 |
| Receivables Turnover | 2.278 |
| Total Asset Turnover | 0.045 |
ABUS Liquidity
| Current Ratio | 8.152 |
| Quick Ratio | 8.152 |
| Cash Ratio | 7.851 |
ABUS Profitability
| Gross Margin | 77.637 |
| Operating Margin | -1,133.917 |
| Pretax Margin | -1,133.042 |
| Net Margin | -1,133.042 |
| Return on Assets | -50.647 |
| Return on Equity | -68.757 |
| Return on Total Capital | -67.566 |
| Return on Invested Capital | -64.349 |
ABUS Capital Structure
| Total Debt to Total Equity | 6.284 |
| Total Debt to Total Capital | 5.912 |
| Total Debt to Total Assets | 4.645 |
| Long-Term Debt to Equity | 5.787 |
| Long-Term Debt to Total Capital | 5.445 |